Company Profile

AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.


Announcements
Directors and Executives
Hartley Atkinson
Executive Director
Marree Atkinson
Executive Director
Anita Baldauf
Independent Director
David Flacks
Chairman
Jon Lamb
Independent Director
Malcolm Tubby
CFO / Company Secretary
John Douglas Wilson Independent Director
Ted Witek
Independent Non-Executive Director
Company Details
Registered Office: Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622
Postal Address: Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622
Telephone: +64 9 488 0232
Facsimile: n/a
Website: www.aftpharm.com
First Listed: 22/12/2015
Balance Date: 31 March
AGM: 06/08/2021
Major Holdings Announcements
Date Name No. Held % Current
16/09/20 Forsyth Barr Group Limited and Fors 1,617,818 71.25 1.55
15/06/20 Hartley Campbell Atkinson and Colin 72,031,609 72.60 69.82
15/06/20 The CRG Persons - 15.99 -
25/05/17 AFT Pharmaceuticals Limited - 72.34 -
Director’s Interests Announcements
Date Name No. Held % Details Other
13/01/22 Jon Lamb 303,764 - - -
14/04/21 Malcolm Tubby 143,892 - - -
10/08/20 Hartley Atkinson 72,899,435 - - -
03/07/20 David Flacks 178,764 - - -
22/08/18 James Burns 125,417 - - -
19/06/17 John Douglas Wilson 56,689 - - -
Analysts’ Forecasts
profit2021 profit2022 eps2021 dps2021 sales2021 ebit2021 ebitda2021
mean 14.0 22.6 13.4 .0 133.6 19.4 20.5
high 14.0 22.6 13.4 .0 133.6 19.4 20.5
low 14.0 22.6 13.4 .0 133.6 19.4 20.5
sample 1 1 1 1 1 1 1
Disclaimer
Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.
Last Updated: 01/03/2022
Energy
Climate change: some bans banned as energy policy evolves
Ian Llewellyn | Tue, 17 May 2022

The Emissions Reduction Plan shows the evolution in the government's thinking on energy policy.

Technology
$20m for SaaS and innovation in the Budget
Ben Moore | Tue, 17 May 2022

A first look at where the digital economy will benefit from government investment.

Charities FREE
Charities regulator more guide dog than watchdog
Oliver Lewis | Tue, 17 May 2022

Regulator opts more for education than enforcement.